Zanubrutinib showed superior PFS and OS compared to acalabrutinib in R/R MCL, with HRs of 0.57 and 0.43, respectively. The STC approach was used due to the lack of head-to-head trials, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback